Clinical Trial of Autologous Adipose Tissue Derived Stromal Cell Therapy for Ischemic Heart Failure

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01709279

Enrollment

Registered

2012-10-18

Start date

2012-08-31

Completion date

2019-09-30

Last updated

2017-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemic Heart Failure

Keywords

Ischemic heart failure, Myocardial regeneration, ADRC

Brief summary

Mesenchymal stem cells have capability to differentiate into myocardium, vascular endothelial cell, vascular smooth muscle cell and will be useful for heart regeneration. Adipose tissue is relatively enriched with mesenchymal stem cell compared to bone marrow tissue. In this trial, eligible ischemic heart failure patients will be proceeded intracoronary administration of autologous adipose tissue derived stromal cells by cardiac catheterization.

Detailed description

The population of the ischemic heart failure patients is enormous in Japan and the only radical treatment for them is heart transplantation: however, the number of giving donor is extremely limited. Mesenchymal stem cells have been capable to differentiate into mesodermal-lineage cells as well as endodermal-lineage cells such as myocardial cell. They reside in the mesenchymal tissues such as bone marrows as well as adipose tissues. The latter tissues are relatively enriched with mesenchymal stem cells compared to bone marrow cells. In this study, the ischemic heart failure patients will undergo intracoronary administration of autologous adipose tissue derived stromal cells through cardiac catheterization.

Interventions

BIOLOGICALadipose tissue derived stromal cells dosage

intra-coronary administration of autologous adipose tissue derived stroma cells

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

20 Years to No maximum

Healthy volunteers

Inclusion criteria

* Heart failure patients occured by prior ischemic event whose ejection fraction must be less than 40%.

Exclusion criteria

* Complicated severe other organ disease. * Patient with malignancy. * History of chemotherapy or irradiation within 4 weeks. * Patient with immunodeficiency * Pregnancy or possibility of pregnancy * Candidate who are judged to be not applicable to this study by doctors.

Design outcomes

Primary

Measure	Time frame
all cause harmful events	6 month

Countries

Japan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026